Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …

… Lana M. Chahine receives support from the Michael J Fox Foundation and receives royalties
from Wolters Kluwel (for book authorship) John Trojanowski may accrue revenue in the …

Background: The effect of the COVID-19 pandemic on people with Parkinson’s disease (PD)
is poorly understood. Objective: To rapidly identify areas of need and improve care in …

Objective: The objective of this study was to assess longitudinal change in clinical and
dopamine transporter imaging outcomes in early, untreated PD. Methods: We describe 5‐year …

Background The objective of this study was to assess neurofilament light chain as a Parkinson's
disease biomarker. Methods We quantified neurofilament light chain in 2 independent …

Objectives To assess the neurobiological substrate of initial cognitive decline in Parkinson’s
disease (PD) to inform patient management, clinical trial design, and development of …

The Parkinson’s disease (PD) research field has seen the advent of several promising
biomarkers and a deeper understanding of the clinical features of the disease from the earliest …

… Lana M. Chahine receives research support from the Michael J. Fox Foundation (MJFF),
has received travel payment from MJFF to MJFF conferences, is a paid consultant to MJFF, …

Background The Parkinson's Progression Markers Initiative (PPMI) is an ongoing observational,
longitudinal cohort study of participants with Parkinson's disease, healthy controls, and …

Objective The Systemic Synuclein Sampling Study (S4) measured α-synuclein in multiple
tissues and biofluids within the same patients with Parkinson disease (PD) vs healthy controls (…